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ABSTRACT
The methylation pattern of cfDNA, isolated from liquid biopsies, is gaining substantial interest for 
diagnosis and monitoring of diseases. We have evaluated the impact of type of blood collection 
tube and time delay between blood draw and plasma preparation on bisulphite-based cfDNA 
methylation profiling. Fifteen tubes of blood were drawn from three healthy volunteer subjects 
(BD Vacutainer K2E EDTA spray tubes, Streck Cell-Free DNA BCT tubes, PAXgene Blood ccfDNA 
tubes, Roche Cell-Free DNA Collection tubes and Biomatrica LBgard blood tubes in triplicate). 
Samples were either immediately processed or stored at room temperature for 24 or 72 hours 
before plasma preparation. DNA fragment size was evaluated by capillary electrophoresis. 
Reduced representation bisulphite sequencing was performed on the cell-free DNA isolated 
from these plasma samples. We evaluated the impact of blood tube and time delay on several 
quality control metrics. All preservation tubes performed similar on the quality metrics that were 
evaluated. Furthermore, a considerable increase in cfDNA concentration and the fraction of it 
derived from NK cells was observed after a 72-hour time delay in EDTA tubes. The methylation 
pattern of cfDNA is robust and reproducible in between the different preservation tubes. EDTA 
tubes processed as soon as possible, preferably within 24 hours, are the most cost effective. If 
immediate processing is not possible, preservation tubes are valid alternatives.
ARTICLE HISTORY
Received 4 May 2020  
Revised 14 August 2020  
Accepted 9 September 2020  
KEYWORDS






The analysis of cell-free tumour-derived DNA 
(ctDNA) isolated from liquid biopsies, including 
blood plasma, has emerged as a complementary 
assay for tumour tissue genomic profiling [1,2]. 
The methylation pattern of cell-free DNA is cur-
rently under investigation as a biomarker for the 
non-invasive diagnosis of both benign [3] and 
malignant [4] conditions. Several algorithms are 
developed to deconvolute the epigenetic signal 
estimating the proportion of cell types contribut-
ing to cell-free DNA makeup [3,5,6].
The current lack of standardization of the pre- 
analytical phase is hampering routine clinical 
implementation. Pre-analytical factors like storage 
conditions and processing time impact cfDNA 
concentrations [7,8]. Blood tubes containing pre-
servation agents aimed at stabilization of white 
blood cells inhibiting them from releasing DNA 
into the plasma have been developed [9] to 
increase the allowed processing delay.
It is unknown to what extent the preservation 
agents have an impact on the methylation pattern of 
cell-free DNA. For example, formaldehyde results in 
deamination of cytosines, thereby resulting in C to 
T transitions [10]. In addition, crosslinking reagents 
can also induce methyl bridges with cytosine and 
guanine through a covalent bond [11]. These bonds 
can interfere with bisulphite conversion efficiency 
required for methylation analysis. As the makeup of 
preservation agents are usually proprietary informa-
tion, the expected theoretical impact on cfDNA is 
generally unknown.
Although several manufacturers claim that their 
tube does not impact cfDNA methylation status 
[12,13], studies are conflicting. One study suggests 
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that PAXgene blood ccfDNA tubes and Streck 
Cell-Free DNA BCT tubes are unsuitable for the 
analysis of methylated cfDNA, as assessed with 
methylation-specific PCR (MSP) for SEPT9 [14]. 
Schröder and Steimer reported a significantly higher 
methylation percentage in whole blood after ten 
months of storage [15]. In contrast, Zavridou and 
colleagues [16] concluded that plasma samples from 
preservation tubes remain suitable for cfDNA 
methylation analysis with methylation specific PCR 
(MSP) when stored at −80°C.
The major drawback of using methylation- 
specific PCR to evaluate pre-analytical variables is 
that only a limited number of loci are analysed. To 
our knowledge, no study has systematically evalu-
ated the effect of various preservation agents and 
the timing of plasma preparation after blood draw 
on the genome-wide methylation pattern. To this 
end, we have collected 45 blood samples in 5 
different blood collection tubes (4 preservation 
tubes and 1 EDTA tube) from 3 healthy volunteers 
and performed plasma preparation at three differ-
ent time points after blood draw followed by 
reduced representation bisulphite sequencing on 
the resulting cell-free DNA (cf-RRBS) [17].
Methods
Healthy volunteers and samples
Blood was drawn from three healthy individuals 
(males and females between 24 and 45 years old). 
15 tubes were drawn per healthy volunteer: 3× BD 
Vacutainer K2E EDTA spray tubes (REF 367,525), 
3× Streck Cell-Free DNA BCT tubes (catalogue 
number 218,962), 3× QIAGEN PAXgene Blood 
ccfDNA tubes (catalogue number 768,115), 3× 
Roche Cell-Free DNA Collection tubes (catalogue 
number 07785674001) and 3× Biomatrica LBgard 
blood tubes (SKU 68,021–001), resulting in 45 
samples in total.
The order of blood draw and collection in 
different tubes was randomized per donor. 
Seven tubes were collected from one antecubital 
vein and eight tubes were collected from the 
contralateral antecubital vein with the BD 
Vacutainer push button 21 G, 7” tube with pre- 
attached holder tube butterfly needle system 
(REF 367,355). The ethical committee of Ghent 
University Hospital approved the study (identi-
fier 2017/1207) and written consent was obtained 
from all volunteers enrolled in this study. The 
tubes are abbreviated as ‘EDTA’ (BD Vacutainer 
K2E EDTA spray tubes), ‘Streck’ (Streck Cell- 
Free DNA BCT tubes), ‘Roche’ (Roche Cell-Free 
DNA collection tubes), ‘PAXgene’ (QIAGEN 
PAXgene Blood ccfDNA tubes) or ‘Biomatrica’ 
(Biomatrica LBgard blood tubes). Descriptive sta-
tistics were performed with R v3.5.1 and are 
reported as median and 25th (Q25) and 75th 
percentile (Q75) values [interquartile range].
Sample collection and processing
After blood draw, samples were either immediately 
processed to plasma (1 per tube type, per donor; 15 
tubes in total), or incubated at room temperature for 
24 hours (n = 15) or 72 hours (n = 15). Tubes that 
were incubated were shielded from direct sunlight on 
a lab bench in a climate-controlled environment. 
Plasma was prepared according to a previously pub-
lished protocol developed at the Ghent University 
Hospital [18] (EDTA and Streck, 10 min at 1600 rcf 
followed by 10 minutes at 16,000 rcf or PAXgene, 
15 min at 1900 rcf) or according to the manufac-
turers’ guidelines (Roche, 10 min at 1600 rcf and 
Biomatrica, 15 min at 1900 rcf followed by 15 min 
at 4500 rcf). Acceleration and deceleration were set to 
2 across all centrifugations (Eppendorf centrifuge 
5804, Eppendorf). Plasma was aliquoted per 
1500 µL and stored at −80°C until further processing.
Cell-free DNA extraction
cfDNA was extracted using the Maxwell RSC LV 
ccfDNA kit (Promega). Isolation of cfDNA was 
done starting from 1500 µL of plasma. DNA 
extraction was performed according to the manu-
facturer’s instructions. DNA was eluted in 75 μL of 
elution buffer (Promega).
Cell-free DNA quality control
DNA concentration was measured using the Qubit 
high-sensitivity kit (Thermo Fisher Scientific). DNA 
concentration and size distribution was measured 
using the FEMTO Pulse Automated Pulsed-Field 
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CE Instrument (Agilent) according to the manufac-
turer’s instructions (NGS Kit, FP-1101-0275).
RRBS library construction
Library construction was performed according to the 
methods described by De Koker et al [17] with the 
following three modifications: [1] The complete elu-
ate that was remaining after quality control (2 µL 
Qubit and 2 µL Femto PULSE) was used for library 
construction (= 71 µL). For this, samples were con-
centrated with a vacuum centrifuge (SpeedVac, 
Thermo Fischer Scientific, V-AQ programme) at 35° 
C and nuclease-free water was added to a volume of 
11.1 μL. Unmethylated lambda phage DNA (0.005 ng, 
or 0.5 µL of a 0.01 ng/µL solution) was added to the 
eluate after the SpeedVac step. [2] Libraries prepared 
using the cf-RRBS protocol were cleaned by magnetic 
bead selection (AMPure XT beads – NEB) and eluted 
in 0.1× TE buffer. The libraries were visualized with 
the Fragment Analyser (Agilent) and quantified using 
the Kapa library quantification kit for Illumina plat-
forms (Kapa Biosystems). [3] Based on the concentra-
tion, the libraries were equimolarly pooled and were 
sequenced on a NovaSeq 6000 instrument with 
a NovaSeq SP kit (paired-end, 2 × 50 cycles), using 
3% phiX and a loading concentration between 1.8 and 
2.5 nM. A maximum of 15 samples were pooled in 
one sequencing run, and samples from different 
donors and tubes were mixed to avoid sequencing 
batch effects.
Sequencing quality control and mapping
After sequencing, bcl files were demultiplexed using 
bcl2fastq v2.19.1.403. The raw fastq files were first 
quality checked with FastQC v0.11.5 [19]. Adaptors 
were removed with Trim Galore v0.6.0 (with flags – 
three_prime_clip_R1 1 – three_prime_clip_R2 1 – 
clip_R1 3 – clip_R2 3 to remove methylation bias at 
the three or five prime end due to the MspI restriction 
digest) and CutAdapt v1.16 [20]. Processed fastq files 
were again quality checked with FastQC. Mapping to 
GRCh37 was done with Bismark v0.20.1 [21] with 
default parameters. Optical duplicates were removed 
with Picard v2.18.27 (http://broadinstitute.github.io/ 
picard/), with parameters OPTICAL_DUPLICATE_ 
PIXEL_DISTANCE = 12,000, REMOVE_SEQUENC 
ING_DUPLICATES = true, TAGGING_POLICY = 
OpticalOnly, READ_NAME_REGEX = [a-zA- 
Z0-9]+:[0–9]+:[a-zA-Z0-9]+:[0–9]+:([0–9]+):([0– 
9]+):([0–9]+)_[0–9]+:[a-zA-Z0-9]+:[0–9]+:[a-zA 
-Z0-9]+’). The bait and target regions were defined 
as the MspI regions between 20–200 bp in GRCh37 
(see ‘NNLS deconvolution) and the number of 
reads in these regions were counted with Picard 
(hsmetrics module. Per-sample information is 
available in supplementary table 1. Figures were 
made with the R programming language (see 
‘code availability’)
Quality control metric development
In order to evaluate tube stability across time points, 
we determined 6 metrics per blood collection tube: [1] 
percentage of reads mapping within MspI regions, [2] 
evolution of relative DNA concentration (as assessed 
by the ratio of reads mapping to the human genome 
versus reads mapping to the lambda genome), [3] 
genome-wide CpG methylation percentage, [4] Total 
number of CpGs covered with at least 15 reads, [5] 
reproducibility of individual cytosine in CpG context 
calls by calculating the area-left-of-the-curve [22] 
(ALC) and [6] the evolution of the immune cell 
content.
In order to not selectively favour samples that 
have been sequenced deeper compared to others, 
we down-sampled all libraries to 18 million read 
pairs with seqtk v1.3 (random seed = 18).
For metrics that are described in percentages 
(e.g. reads mapping within MspI regions, genome 
wide methylated CpG, reproducibility with ALC, 
and immune cell contribution) the absolute 
change (e.g. genome-wide CpG % at T24 minus 
genome-wide CpG % at T0) was calculated across 
all timepoints per donor (excluding the T24-T72 
comparison), resulting in six absolute change 
values. For all other metrics (cell-free DNA con-
centration and number of CpG reaching 15 reads), 
we calculated the fold-change (e.g. across all time-
points per donor, resulting in 6 fold-change values 
(e.g. for donor 1: T0 vs T24, T0 vs T72, times three 
donors, illustrated in Figure 1).
Differential methylation of promotor regions
In order to assess differentially methylated promotor 
regions (DMRs), we used edgeR [23] 3.28.1. Promotor 
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regions were defined as 1000 bp upstream to 2000 bp 
downstream of transcription start sites (TSS). 
Uninformative regions (either completely methylated 
or completely unmethylated across all samples) and 
regions with fewer than 15 reads were removed from 
the dataset (n = 3983 remaining regions). Two types 
of comparisons were performed: (1) DMRs were 
determined by comparing all tubes with one another 
in a pairwise manner, exclusively at T0 and (2) DMRs 
were determined within one tube type by comparison 
T0 with T72. The false discovery rate (FDR) cut-off 
was specified at 0.05.
NNLS deconvolution to determine cell type 
contribution
Deconvolution of plasma cfDNA samples was done 
with non-negative least squares (NNLS) matrix 
decomposition as described by Moss and colleagues 
[3] (https://github.com/nloyfer/meth_atlas). CpGs 
were grouped in order to use more mappable reads. 
Input data (cf-RRBS data) was prepared similar to 
Kang et al. [5]. However, we adjusted these regions 
to make them more suited for cf-RRBS data. First, we 
used mkrrgenome [24] to extract all MspI regions 
between 20 and 200 bp from GRCh37. Then, we 
merged all remaining regions within 1 bp from each 
other with BEDtools v2.27.1. Finally, clusters were 
retained if they contain at least 3 CpGs covered on 
the Illumina HM450K array, resulting in 14,103 clus-
ters covering 61,750 probes on the HM450K array. 
We used the Illumina HM450K reference matrix as 
published by Moss and colleagues to perform the 
deconvolution. Similarly, we selected the top 100 
most specific hypermethylated and hypomethylated 
regions per cell type as described by them.
CelFiE deconvolution to determine cell type 
contribution
Deconvolution of plasma cfDNA samples was done 
with CelFiE (commit d3f975f) and its accompanying 
reference dataset [25]. In order to adapt the WGBS 
dataset (sourced from ENCODE [26] and 
BLUEPRINT [27]) for cf-RRBS data, we removed all 
CpGs not covered in cf-RRBS from the WGBS dataset 
(based on the MspI regions between 20 and 200 bp 
generated with mkrrgenome). Afterwards, tissue 
informative markers were generated as described by 
Caggiano and colleagues [25] and deconvolution was 
performed with CelFiE (https://github.com/christacag 




Using the Qubit High Sensitivity kit, we were unable 
to determine the cfDNA concentration in each sample 
(n = 20 samples with a concentration below the Qubit 
quantitative range). Using the Femto PULSE, cfDNA 
concentrations could be assessed in all samples (3.6 
Figure 1. Illustrative example of quality control metric evolution over time for one donor, two tubes and three time points (left) and 
corresponding boxplot of the fold changes per tube (right). T0 = plasma prepared immediately after blood draw, T24 = plasma 
prepared 24 hours after blood draw, T72 = plasma prepared 72 hours after blood draw. The white triangle on the boxplot 
corresponds to the mean.
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ng/mL plasma [1.75–4.88]) (see next paragraph). At 
later timepoints, the second and third nucleosome 
peaks are less apparent on the capillary electrophero-
grams in the Roche, Biomatrica and DNA Streck 
tubes (Figure 2). cf-RRBS library construction was 
successful in all samples. After sequencing, all libraries 
were down-sampled to 18 M read pairs. 95.0% [92.-
0–96.0] of the total reads were remaining after adaptor 
removal. One healthy volunteer showed fewer reads 
remaining after adaptor removal in all 15 samples 
(supplementary Figure S1). Overall, 63.66% [62.92–-
64.67] of all reads mapped uniquely to the human 
reference genome (GRCh37, supplementary Figure 
S2). Furthermore, we noticed a monotonous increase 
in mapping efficiency in EDTA tubes over time. We 
assessed bisulphite conversion efficiency by calculat-
ing the genome wide CHH methylation percentage. 
A conversion efficiency of 99.3% [99.2–99.4] was 
observed and was similar in all tubes and across all 
three time points (supplementary Figure S4). We 
assessed MspI efficiency by evaluating the percentage 
of reads mapping within all theoretical MspI frag-
ments between 20 and 200 bp. Overall, 89.71% [88.-
28–91.01] of reads mapped within these regions, with 
no tube showing a substantial and consistent change 
between time points (supplementary Figure S5).
cfDNA content
After DNA isolation and before library construction, 
50 pg of lambda DNA was added to all samples. By 
assessing the ratio of the reads mapping to the human 
genome versus the reads mapping to the lambda 
genome, we calculated the (lambda equivalent) 
cfDNA concentration in ng/mL plasma (Figure 3(a, 
b)). The EDTA tubes revealed a substantial increase in 
DNA concentration after 72 hours with an overall 
mean fold change of 4.06 (median concentration at 
T0 = 2.98 ng/mL plasma, median concentration at 
T72 = 12.65 ng/mL plasma). In contrast, the Roche 
tubes revealed a considerable decrease in DNA con-
centration after 72 hours with an overall mean fold 
change of 4.61 (median concentration at T0 = 2.45 ng/ 
mL plasma, median concentration at T72 = 0.46 ng/ 
mL plasma). We confirmed these findings by Femto 
PULSE quantification (Figure 2, supplementary 
Figures S13 and S14). The cfDNA concentration mea-
sured with Femto PULSE correlated well with the 
sequencing based cfDNA (lambda equivalent) 
concentration determination (Pearson’s r = 0.73, sup-
plementary Figure S6).
Overall CpG methylation (Figure 3(c,d)) slightly 
increases in EDTA tubes across time (mean abso-
lute change = 4.33%, median % mCpG at 
T0 = 43.29%, median % mCpG at 
T72 = 49.21%). While the absolute number of 
CpG covered increases in EDTA tubes across 
time (median number of CpGs at T0 = 3,287,720, 
median number of CpGs at T72 = 4,438,485), the 
number of CpGs with at least 15 supporting reads 
is relatively stable (median number of CpGs at 
T0 = 487,450, median number of CpGs at 
T72 = 517,884). In contrast to EDTA, the number 
of CpGs with at least 15 counts decreased in 
Biomatrica, DNA Streck and Roche tubes (Figure 
3(e-h)).
Principal component analysis reveals clustering 
based on the donor, indicating the blood tube, 
sequencing or plasma preparation protocol are not 
the dominant drivers in explaining the variance in the 
methylation pattern of the cfDNA (Figure 4). Within 
each donor, timepoints were evaluated for reproduci-
bility at the CpG level. The cumulative distribution of 
the difference between CpG methylation fractions was 
visualized. On this visualization, the area left of the 
cumulative distribution curve (ALC) is a marker for 
reproducibility between these two replicates, with 
increasing ALC values indicating lower reproducibil-
ity (described by Mestdagh et al. [22].). The six ALC 
values per tube were similar across all tubes (supple-
mentary figures S7, S8). Furthermore, no differentially 
methylated promotor regions were detected in any of 
the across-tube comparisons at T0 (supplementary 
table 2). In addition, no DMRs were observed for 
the Biomatrica, DNA Streck, PAXgene after compar-
ison between T0 and T72, while the Roche tube con-
tained 2 DMRs (MAGI1-AS1, SLX1B-SULT1A4) and 
the EDTA tube contained 51 DMRs (1.29%, 44 upre-
gulated and 7 downregulated) (supplementary 
table 2). Among the top enriched KEGG pathways 
of the genes linked to the 51 DMRs, we identified 
upregulation of the apoptosis pathway (FDR = 0.014). 
FRY enrichment for GO:0006915 (apoptotic process) 
and GO:0030101 (natural killer cell activation) 
revealed significant upregulation for these pathways 
(FDR = 0.014 and 0.029, respectively). Further com-




In order to evaluate changes in cell contributions to 
cfDNA content, we performed non-negative least 
squares (NNLS) on the cfDNA samples in combina-
tion with a previously published cfDNA reference 
atlas (generated on Illumina arrays) [3]. In order to 
compare cf-RRBS with Illumina HM450K or EPIC, 
we grouped individual CpGs into regions as described 
before [2]. We observed similar proportions of ery-
throcyte progenitors as described by Moss et al. 
Figure 2. Capillary electropherograms (Femto PULSE) of all 15 cfDNA samples obtained from donor 2. RFU = relative fluorescence 
units. T0 = plasma prepared immediately after blood draw, T24 = plasma prepared 24 hours after blood draw, T72 = plasma 
prepared 72 hours after blood draw. Peaks at 1 and 6000 bp correspond to the lower marker (1 bp) and upper marker (6000 bp).
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Figure 3. (a) Evolution of cfDNA concentration calculated based lambda DNA spike-in after DNA isolation and before library construction, (b) 
Boxplot of fold changes within each donor across timepoints per tube for cfDNA concentration. (c) Evolution of the genome-wide CpG 
methylation percentage, split per tube, (d) Boxplot of the absolute change within each donor across timepoints per tube for the genome-wide 
CpG methylation percentage. (e) Evolution of the absolute number of CpGs detected before setting a read count cut-off, split per tube, (f) 
Boxplot of the fold change within each donor across timepoints per tube absolute number of CpGs detected. (G and H) Evolution and boxplot of 
fold change of absolute number of CpGs detected after setting a read count cut-off of 15 reads. (I and J) Evolution of natural killer cell 
contribution, split per tube, calculated with NNLS using human methylation 450 K and EPIC micro-array data as reference dataset or with CelFiE, 
using public whole genome bisulphite sequencing data from ENCODE/BLUEPRINT as reference set. (K and L) Boxplot of absolute changes in NK 
cell fractions within each donor across timepoints per tube. The white triangle on the boxplot corresponds to the mean of the absolute change. 
NK, natural killer cell. T0 = plasma prepared immediately after blood draw, T24 = plasma prepared 24 hours after blood draw, T72 = plasma 
prepared 72 hours after blood draw.
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(35.80% [28.70–41.80]). In all EDTA tubes at T72, 
a sharp increase of natural killer (NK, Figure 3(e,f)) 
cell fraction was observed (mean absolute 
change = 20.53, median at T0 = 0%, median at 
T72 = 39.6%) and a decrease of neutrophil fraction 
was observed (mean absolute change = 19.53, med-
ian at T0 = 40.8%, median at T72 = 7.8%, supple-
mentary Figures S9 and S10).
In order to confirm these results, we used an inde-
pendent reference dataset and deconvolution method 
(CelFiE) [25]. We observed similar changes in NK cell 
contribution (Figure 3(g,h)), with a mean absolute 
change of 13.81% in EDTA tubes (median at 
T0 = 3.12%, median at T72 = 31.97%). The decrease 
of neutrophil fraction was less pronounced (supple-
mentary Figures S11 and S12). Furthermore, CelFiE 
identified an overall unknown cell type percentage of 
12.48% [9.36–16.59] across all samples.
Discussion
The standardization of the pre-analytical phase is one 
of the major hurdles in incorporating liquid biopsy- 
based assays in clinical trials and routine. Several 
companies have developed ‘preservation tubes’ that 
stabilize blood cells and prevent haemolysis and 
degradation of white blood cells over time. The cell- 
free DNA methylation pattern is currently under 
investigation as a marker for screening, diagnosis 
and therapy response monitoring [28]. We have inves-
tigated the impact of the preservation agent on the 
cfDNA methylation pattern in EDTA and in four 
preservation tubes (Roche, Streck, PAXgene and 
Biomatrica). Time points were selected based on 
a clinical situation where samples are stored at room 
temperature over a weekend. Although the cf-RRBS 
still does not investigate the full methylome, there is 
a strong correlation with whole genome bisulphite 
sequencing (r = 0.98) and SeqCap Epi CpGiant cap-
ture sequencing (Roche, r = 0.96) for the covered 
CpGs [17]. Thus, our results can be generalized to 
these bisulphite-based alternatives for cell-free DNA 
methylation assessment.
We were able to obtain libraries from all samples, 
indicating that the cf-RRBS library construction 
method is robust in samples with very low amounts 
of cfDNA (100 pg total input). Bisulphite conversion 
efficiency was > 99% in all tubes, indicating there is no 
incompatibility with the EZ DNA Lightning kit used 
in this study and the preservation agent (e.g. due to 
crosslinking of DNA). Thus, changes in genome wide 
CpG methylation percentage reflect changes in 
cfDNA composition, rather than a technical artefact.
The estimated cell-type contributions in our sam-
ples, obtained from healthy volunteers, are similar to 
what has previously been described by Moss [3] and 
Caggiano [25], with the majority of cfDNA is originat-
ing from leukocytes. Furthermore, a smaller but 
Figure 4. Principal component analysis performed on the beta values (fraction of methylated reads), with common cytosines in 
a CpG context across all samples (at least 15 reads per cytosine, n = 6706).
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substantial fraction of the cfDNA is derived from 
erythrocyte progenitors in these two studies, and our 
results further support these findings. While earlier 
studies have seen that the hepatocyte-derived fraction 
is the second-most abundant fraction in the cfDNA 
(up to 10%) [6], these more recent studies do not 
support this. Furthermore, our results show that the 
content and cfDNA yield substantially change when 
storing EDTA for 72 hours at room temperature. 
More specifically, we observed a substantial increase 
in NK cell contribution with both computational 
deconvolution and gene set enrichment analysis. 
Possibly, NK cells are more vulnerable to cellular 
stress, and degrade or lyse faster compared to other 
white blood cells. Previous research based on flow 
cytometry [29] showed that, although NK cells are 
more vulnerable to storage than B or T cells, mono-
cytes and myeloid cells are even less stable than NK 
cells. Our data could not confirm this. The authors 
recommend against performing immunophenotyping 
of white blood cells beyond 48 hours.
The most important limitation of this study is 
the small sample size. Thus, small differences 
should be interpreted with care. However, while 
only three biological replicates are available per 
condition (i.e. tube and time point), the quality 
control metrics are reproducible.
Based on the low cost of EDTA tubes, we recom-
mend using EDTA tubes for cfDNA applications 
in situations where it is possible to immediately 
(within 24 hours) process the blood samples. If, 
due to logistic or practical reasons this is not fea-
sible, a tube containing a preservation agent could 
be used. The type and brand of preservation tube 
should be selected on a per-study basis. For exam-
ple, Roche tubes are not desirable in experiments 
that require larger amounts of DNA, as we have 
observed a decrease in cfDNA concentration over 
time. In studies where both cfRNA and cfDNA are 
being investigated, a preservation tube with the best 
overall performance should be selected [30]. For 
example, DNA Streck tubes are incompatible with 
the analysis of extracellular RNA [31]. Other pre-
servation tubes have been developed since the 
initiation of this study (e.g. Norgen cf-DNA/cf- 
RNA preservation tubes) and should be evaluated 
in a similar manner before using them for cfDNA 
methylation-based studies. Nikolaev and colleagues 
[32] have shown that other preservation tubes 
mitigate the effect of other pre-analytical factors, 
e.g. storage temperature and long term (~1 week) 
storage. While we did not investigate the effect of 
storage beyond 72 hours, we expect that changes in 
cfDNA methylation beyond 72 hours will be pri-
marily driven by changes in cell-type contribution 
rather than the preservation agent used in these 
tubes. Still, thorough validation and quality control 
as emphasized by others [8,32] remains essential. 
More recently, Gerber and colleagues [33] further 
provided evidence for the use of EDTA tubes if fast 
processing is possible, and to use leukocyte- 
stabilizing tubes (Streck Cell-Free DNA BCT 
tubes, PAXgene Blood ccfDNA tubes, Roche Cell- 
Free DNA Collection tubes) if a delay between 
blood draw and plasma preparation is expected. 
Not only were the preservation tubes suitable for 
ctDNA extraction in combination with low cover-
age whole genome sequencing and digital droplet 
PCR, but also for characterizing leukocyte subpo-
pulations (with flow cytometry), circulating tumour 
cells and germline DNA from blood.
Additionally, our study adds that capillary electro-
phoresis with Femto PULSE is a valid approach for 
evaluating the presence of contaminating high mole-
cular weight DNA, with minimal sample loss (10 pg).
In conclusion, the preservation agent used in Streck 
Cell-Free DNA BCT tubes, PAXgene Blood ccfDNA 
tubes, Roche Cell-Free DNA Collection tubes and 
Biomatrica LBgard blood tubes does not seem to 
give bias towards global or local hypo- or hypermethy-
lation. However, EDTA tubes show a good perfor-
mance in situations where they are processed within 
24 hours after blood draw and thus have a higher cost/ 
benefit ratio.
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